These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

97 related articles for article (PubMed ID: 25899534)

  • 1. Reply to: "Evidence supporting a beneficial role of vitamin D in chronic hepatitis C".
    Kitson MT; Sarrazin C; Toniutto P; Roberts SK
    J Hepatol; 2015 Aug; 63(2):531-2. PubMed ID: 25899534
    [No Abstract]   [Full Text] [Related]  

  • 2. Evidence supporting a beneficial role of vitamin D in chronic hepatitis C.
    Pang Q; Qu K; Zhang JY; Liu C
    J Hepatol; 2015 Aug; 63(2):530-1. PubMed ID: 25908272
    [No Abstract]   [Full Text] [Related]  

  • 3. Vitamin D level and sustained virologic response to interferon-based antiviral therapy in chronic hepatitis C: a systematic review and meta-analysis.
    Kitson MT; Sarrazin C; Toniutto P; Eslick GD; Roberts SK
    J Hepatol; 2014 Dec; 61(6):1247-52. PubMed ID: 25135863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Twelve-week posttreatment follow-up predicts a sustained virological response to pegylated interferon and ribavirin therapy.
    Aghemo A; Rumi MG; De Nicola S; Colombo M
    Hepatology; 2010 Sep; 52(3):1170-1. PubMed ID: 20812363
    [No Abstract]   [Full Text] [Related]  

  • 5. Peginterferon and ribavirin for hepatitis C.
    Abramowicz M
    N Engl J Med; 2007 Mar; 356(12):1270-1; author reply 1271. PubMed ID: 17378100
    [No Abstract]   [Full Text] [Related]  

  • 6. Pegylated-interferon plus ribavirin for HCV-positive indolent non-Hodgkin lymphomas.
    Mazzaro C; De Re V; Spina M; Dal Maso L; Festini G; Comar C; Tirelli U; Pozzato G
    Br J Haematol; 2009 Apr; 145(2):255-7. PubMed ID: 19239472
    [No Abstract]   [Full Text] [Related]  

  • 7. Ribavirin with interferon for hepatitis C in dialysis patients: efficacious and safe in the right patients in good hands.
    Mutimer D
    Gut; 2015 Feb; 64(2):190-1. PubMed ID: 24861270
    [No Abstract]   [Full Text] [Related]  

  • 8. Vitamin D levels in Egyptian HCV patients (genotype 4) treated with pegylated interferon.
    Mohamed AA; Sabry NA; Abbassi MM; Ibrahim WA; Ali-Eldin ZA
    Acta Gastroenterol Belg; 2013 Mar; 76(1):38-44. PubMed ID: 23650781
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response-guided therapy: optimizing treatment now and in the future.
    Marcellin P; Rizzetto M
    Antivir Ther; 2008; 13 Suppl 1():1-2. PubMed ID: 18432156
    [No Abstract]   [Full Text] [Related]  

  • 10. [Sofosbuvir: alternative in hepatitis C infection?].
    Blum HE
    Dtsch Med Wochenschr; 2013 Aug; 138(33):1646-7. PubMed ID: 23913349
    [No Abstract]   [Full Text] [Related]  

  • 11. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Hsu CS
    N Engl J Med; 2013 Aug; 369(7):678. PubMed ID: 23944317
    [No Abstract]   [Full Text] [Related]  

  • 12. Sofosbuvir for previously untreated chronic hepatitis C infection.
    Lawitz E; Gane EJ
    N Engl J Med; 2013 Aug; 369(7):678-9. PubMed ID: 23944316
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of interleukin-28B on treatment outcome in hepatitis C virus G1/4 patients receiving response-guided therapy with pegylated interferon alpha-2a/ribavirin.
    Pearlman BL; Ehleben C
    Hepatology; 2012 May; 55(5):1645. PubMed ID: 22212908
    [No Abstract]   [Full Text] [Related]  

  • 14. Peginterferon and ribavirin for chronic hepatitis C.
    Hoofnagle JH; Seeff LB
    N Engl J Med; 2006 Dec; 355(23):2444-51. PubMed ID: 17151366
    [No Abstract]   [Full Text] [Related]  

  • 15. [Sofosbuvir for hepatitis C - is brevity the soul of wit?].
    Zimmermann HW; Tacke F
    Z Gastroenterol; 2013 Sep; 51(9):1110-2. PubMed ID: 24022206
    [No Abstract]   [Full Text] [Related]  

  • 16. Peginterferon plus ribavirin for hepatitis C in HIV-infected patients.
    Gholam PM
    N Engl J Med; 2004 Nov; 351(22):2340-2; author reply 2340-2. PubMed ID: 15570682
    [No Abstract]   [Full Text] [Related]  

  • 17. [Telaprevir, PEG-IFNα-2b and ribavirin combination therapy for difficult to treat patients with genotype 2 chronic hepatitis C].
    Nishimura T
    Nihon Rinsho; 2015 Dec; 73 Suppl 9():193-8. PubMed ID: 26845929
    [No Abstract]   [Full Text] [Related]  

  • 18. Pretreatment prediction of virological response to peginterferon plus ribavirin therapy in patients with chronic hepatitis C, using viral and host factors: some concerns.
    Dai CY; Chuang WL; Huang JF; Hsieh MY; Yu ML
    Hepatology; 2009 Jun; 49(6):2125; author reply 2125-6. PubMed ID: 19479790
    [No Abstract]   [Full Text] [Related]  

  • 19. Mild hepatitis C: treat or monitor.
    Main J; Thomas H
    J Viral Hepat; 2006 May; 13(5):289. PubMed ID: 16637857
    [No Abstract]   [Full Text] [Related]  

  • 20. Menopause, and not age, is a critical factor associated with a worse response to antiviral therapy in women affected by chronic hepatitis C.
    Gitto S; Karampatou A; Andreone P; Villa E
    Int J Infect Dis; 2012 Feb; 16(2):e149. PubMed ID: 22209229
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.